Pharma's Love Affair With Dealmaking: No End In Sight
Executive Summary
The pace of pharma dealmaking continued unabated in 2015, climaxing with Pfizer’s agreed $160 billion merger with Allergan. Conditions are right for this situation to persist, at least for the foreseeable future.
You may also be interested in...
Mylan Finally Nabs Meda In Diversification Play
Deal coincides with full year/fourth quarter earnings release.
Value-Based R&D Pharma Productivity 2015: Oncology And Hep C Drive Top Performers
Catenion updates its annual list of the year's top pharma R&D performers, based on R&D productivity and growth.
Finding The Fit For Ophthalmology In The New Pfizer
The merger of Pfizer and Allergan might raise broader questions about the fairness – or long-term viability – of the corporate tax code in the US. But it also has generated some angst over Allergan’s future as a stalwart in ophthalmology.